Mild Mitochondrial Impairment Activates Overlapping Longevity Pathways Converging on the Flavin-Containing...

Area of Science:

• Molecular Biology
• Genetics
• Aging Research

Background:

• Mitochondrial dysfunction can trigger stress responses that influence lifespan.
• Hypoxia-inducible factor 1 (HIF-1) is a key mediator in hypoxia stress response and lifespan extension.
• Flavin-containing monooxygenase-2 (FMO-2) has been identified as a downstream target in HIF-1-mediated longevity.

Purpose of the Study:

• To investigate the specific role of flavin-containing monooxygenase-2 (fmo-2) in the extended lifespan of genetic mitochondrial mutants in C. elegans.
• To identify upstream signaling pathways and transcription factors that regulate fmo-2 expression in the context of mitochondrial longevity.

Main Methods:

• Analysis of fmo-2 gene expression in long-lived mitochondrial mutants (clk-1, isp-1, nuo-6) of C. elegans.
• RNA interference (RNAi) and genetic mutation to disrupt fmo-2 function.
• Examination of the requirement for signaling molecules (HLH-30, NHR-49, MDT-15) and longevity pathways (DAF-16, PMK-1, SKN-1, CEH-23, AAK-2, HIF-1, ELT-2) in fmo-2 upregulation and lifespan extension.

Main Results:

• fmo-2, but not other FMO genes, was specifically upregulated in long-lived mitochondrial mutants.
• Disruption of fmo-2 significantly shortened the lifespan of these mutants, confirming its essential role in longevity.
• Upregulation of fmo-2 and the extended lifespan of mitochondrial mutants were dependent on signaling molecules HLH-30, NHR-49, MDT-15, and longevity pathways including DAF-16, PMK-1, SKN-1, CEH-23, AAK-2, HIF-1, and ELT-2.

Conclusions:

• FMO-2 is a critical downstream effector required for lifespan extension in C. elegans with impaired mitochondrial function.
• Multiple longevity pathways converge on the upregulation of fmo-2, highlighting its central role in integrating stress response and aging.
• This study elucidates key molecular mechanisms underlying mitochondrial longevity and identifies FMO-2 as a common target for lifespan modulation.